Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2004

View Archived Issues

Update on the antitumor efficacy of MDX-010

Durect and NeuroSystec enter development agreement for inner ear disorders

Senetek licenses Invicorp to Ardana for Europe

Phase II ramoplanin trial in C. difficile-associated diarrhea completes enrollment

NovaDel Pharma submits NDA for aerosol nitroglycerin lingual spray

Safety issues associated with Pivanex plus docetaxel in phase IIb study

Mechanisms of femoral fracture healing in rats by TP-508

Sustained clinical response achieved with abatacept in rheumatoid arthritis

CuraGen and Seattle Genetics sign ADC technology agreement

Schering-Plough licenses garenoxacin rights from Toyama

Merck & Co. and Vertex collaborate on development of VX-680

Synthetic adrenal steroid hormones protect from chemotherapy or radiation-induced myelodepression

Novel synthetic glycolipid promising against hepatitis B and C viruses

Characterization of a novel noncompetitive antagonist of GluK5 receptors

Antiischemic nitric oxide donor effective against thrombosis in vivo

Merger of CellExSys and Chromos Molecular Systems

Merck & Co. and NitroMed collaborative COX-2 inhibitor enters phase II

Positive interim results from phase II trial of FK-228 in CTCL and PTCL

Merix Bioscience and Kirin Brewery collaborate on dendritic cell vaccines

New phase II study of talabostat in CLL

Merck scientists present more GABA-A receptor ligands for anxiety and other uses

New IP receptor antagonists and their use in urological disorders claimed by Bayer

New HNE inhibitors and their use covered by AstraZeneca patent

Theravance presents new muscarinic M2 antagonists with utility in overactive bladder

Dual dopamine D2/5-HT2A antagonists identified by Pfizer scientists

Vertex claims new inhibitors of ROCK and other kinases

New antiangiogenic agents in early development at Bayer

Preclinical studies on possible effects of anti-human Fas antibody R-125224 in autoimmune diseases

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026